亞盛醫藥-B(06855.HK)奧雷巴替尼及APG-2575多項臨床進展將美國血液學會年會展示
亞盛醫藥-B(06855.HK)公布,奧雷巴替尼(商品名:耐立克)及APG-2575(Lisaftoclax)有多項臨床進展獲選第65屆美國血液學會(ASH)年會展示,其中2項為獲口頭報告。
奧雷巴替尼在多種實體瘤和血液腫瘤治療領域具有廣闊潛力。研究數據顯示,在既往TKIs耐藥/不耐受的CML-CP患者中,與對照現有最佳療法(BAT)治療組相比,奧雷巴替尼治療組在無事件生存期(EFS)顯示統計學和臨床上顯著意義的改善,達到該研究的主要研究終點。
此外,APG-2575 (lisaftoclax)是公司自主研發的新型口服Bcl-2選擇性抑制劑,在多種血液腫瘤和實體瘤治療領域具備廣闊的治療潛力。APG-2575 (lisaftoclax)將在此次ASH年會上展示的治療慢性淋巴細胞白血病(CLL)患者的數據再次證明,該品種在既往接受過深度治療、且BTK經治的CLL患者中療效顯著且耐受性良好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.